stockrow
Friday 6 November 2026
Export LQDA’s income statement to Excel — free account
Liquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
44.69
2.69
−5.68%
Follow LQDA
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 5 | 7 | 7 |
| (184.04%) | (111.05%) | 28.18% | 131.82% | ||
| (46.13%) | (24.69%) | 7.09% | 35.57% | ||
ROIC |
(117.51%) | (70.71%) | 44.72% | 121.05% | |
Return on Tangible Assets |
(90.71%) | (46.11%) | 10.93% | 48.98% | |
Average Days of Receivables |
189.62 | 124.71 | 93.96 | 87.90 | |
Free Cash Flow per Share |
(1.21) | (0.47) | 0.47 | 1.70 | |
Free Cash Flow |
(104.32) | (40.02) | 41.15 | 150.69 | |
Capital Expenditures |
(3.58) | (4.34) | (6.84) | (17.01) | |
| Other line items | |||||
Cash ROIC |
(28.04%) | (9.38%) | 8.08% | 22.99% | |
Accounts Receivable Turnover |
3.45 | 5.57 | 7.64 | 7.61 | |
Accounts Payable Turnover |
1.81 | 3.17 | 2.40 | 2.79 | |
Inventory Turnover |
0.61 | 1.10 | 1.58 | 1.58 | |
Average Days of Payables |
291.33 | 101.38 | 170.00 | 138.36 | |
Days of Inventory on Hand |
1,187.50 | 656.07 | 441.31 | 392.64 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
56.07% | 24.81% | 15.58% | 12.43% | |
Selling, General and Administrative Expense of Revenue |
188.02% | 99.28% | 60.42% | 42.73% | |
Share Based Compensation of Revenue |
39.43% | 18.62% | 10.85% | 7.69% | |
Interest Coverage |
(4.93) | (2.13) | 1.75 | 6.33 | |
Operating CF/Net income |
0.83 | 0.52 | 2.15 | 1.21 | |
Depreciation/Fixed assets |
0.16 | 0.13 | 0.08 | 0.05 | |
Capex/Depreciation |
(2.07) | (2.84) | (4.34) | (10.05) | |
Revenue per Share |
0.80 | 1.84 | 3.27 | 5.07 | |
Operating CF per Share |
(1.17) | (0.41) | 0.55 | 1.89 | |
Capex per Share |
(0.04) | (0.05) | (0.08) | (0.19) | |
Capex to Sales |
0.05 | 0.03 | 0.02 | 0.04 |
Columns are period end dates · fundamentals updated 26 Oct 2026